Wed, Jul 30, 2014, 6:37 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Sunesis Pharmaceuticals, Inc. Message Board

  • StockInformant StockInformant Jan 26, 2011 7:33 PM Flag

    Analysts on the SNSS Website

    2 strong buys and 1 buy... What's the issue been since December? P3 is announced and stock loses one-third of it's value. Either RS is a highly probable event or the market is completely ignoring any potential here. Where's the clown hedge fund manager who stated SNSS was worth $3 + per share...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • R/S is almost sure, the only way to avoid it is to announce a partnership. Last outrageous diluition makes me think they want to go for the long run on their own.
      However, if I am wrong and they sign a partnership, I wouldn't announce it now, I would wait the end of February and let the shorters play their game and then squeeze them, this would be wonderful! But honestly it doesn't look probable at present

      • 4 Replies to brunodc
      • Sunesis is not going to carry 320 million shares (or more) for the next two years.
        When all is said and done, 25-30 million shares going forward.

        The (final?) update of Ph. II during asco may cause buying pressure. With the impending smaller float,
        the price increase could be substantial.

        With possible approval in 18 months,
        30 million shares x $30 a share = 900 million AML market.

        ALSO, 1 for 10 means squat to the big players.
        They will be sitting on 10 million shares at $2.75, looking at potential of $25-$30.

    • i think its gonna come down to the companys (snss) upcoming quarterly report

 
SNSS
7.00+0.22(+3.24%)Jul 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.